Clinical trial
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
NCT00215462 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00215462 |
|---|---|
| Title | Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma |
| Official title | A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer, Stomach Cancer |
| Intervention type | Drug |
| Interventions | Vinorelbine |
| Enrollment | 32 |
| Start date | Jun 1, 2000 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: